金吾财讯 | 梯瓦制药（TEVA）完成总规模约49亿美元等值优先票据的发行定价。本次发行共分为五个批次：10亿欧元2033年到期票据，票面利率4.25%；5亿欧元2036年到期票据，票面利率4.625%；10亿美元2034年到期票据，票面利率5.5%；10亿美元2037年到期票据，票面利率5.75%；12亿美元2032年到期票据，票面利率5.25%。梯瓦制药计划将本次募资净额，叠加公司现有现金，用于赎回存量债务、支付相关发行费用以及一般企业用途。拟赎回的债券包括：2028年到期票面利率6.75%票据，2029年到期票面利率7.875%、7.375%两只可持续发展挂钩票据，部分2027年、2030年到期票据，以及全部2031年到期、票面利率8.125%的可持续发展挂钩票据。这批新票据预计在9月16日前后完成交割。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.